Alliqua Signs Distribution Agreement with Team Distributing International and World Health Industries for SilverSeal® and Hydress® Wound Dressings

LANGHORNE, Pennsylvania, August 13, 2013 /PRNewswire/ --

Alliqua, Inc. (OTCQB: ALQA) ("Alliqua" or "the Company") has signed a distribution agreement with Team Distributing International, LLC ("TDI") of El Dorado, Ark., and World Health Industries, Inc. ("WHI") of Jackson, Miss., by which TDI's and WHI's extensive U.S. sales representative network will distribute Alliqua's SilverSeal^® and Hydress^® wound dressings to physicians and podiatric offices across the country.

Lori Toner, Chief Marketing Officer of Alliqua, said, "This distribution agreement is a significant step forward in Alliqua's effort to raise awareness of its wound dressings. We believe it is a great advantage for patients that healthcare providers working in an office environment be made aware of the antimicrobial properties of Silverseal and the moist wound healing properties of Hydress, and their unique abilities to treat various ulcers like diabetic foot ulcers, as well as minor traumatic wounds. With TDI's and WHI's major focus on the diabetic market, their extensive distribution network represents a great sales and marketing channel for us, and we are very excited about this partnership."

David Johnson, Chief Executive Officer of Alliqua, said, "As part of our strategy is to commercialize our existing wound care products, we are pleased to announce this further build-out in our distribution channel. Partnering with companies like TDI and WHI is essential as Alliqua grows its business and increases its footprint within the healthcare community. Their broad reach should allow our customers to purchase our products with simplicity and ease. We are enthusiastic about this partnership and look forward to keeping investors informed of our progress as we continue to implement our growth strategy."

Dr. Joe Story, Chairman of the Board, World Health Industries, commented: "We share Alliqua's commitment to raising awareness of innovative healthcare products and are pleased it has chosen to work with us. We believe the sales representatives we work with are second-to-none, and are confident they will effectively and efficiently spread the word about SilverSeal and Hydress to the appropriate medical professionals."

Alliqua's SilverSeal is a flexible, sterile hydrogel dressing that incorporates the antimicrobial properties of silver. It is designed for use on partial and full-thickness dermal ulcers, leg ulcers, superficial wounds, abrasions, first and second degree burns, donor sites and over debrided and grafted partial thickness wounds.

Alliqua's Hydress is a cross-linked polymer-based gel that is able to provide and maintain a moist wound environment. There are several benefits associated with increased moisture content, including the cleansing and autolytic debriding of necrotic tissue.

The agreement is a one-year, automatically renewable agreement.  Other terms of the agreement were not disclosed.

About Team Distributing International, LLC

Based in El Dorado, Ark., Team Distributing International, LLC leverages more than 50 years of combined experience in medical sales and marketing. The company offers a wide variety of services including product strategy consulting, sales & marketing support, billing services and assistance at every stage of the R&D process. For more information, please visit http://www.tdihealth.com.

About World Health Industries, Inc.

World Health Industries (WHI) is a leading innovator and one of the premier healthcare distribution, marketing and research companies in the U.S. Operating in 49 states, WHI has subsidiaries specializing in medical devices, DNA testing, toxicology, specialty compounding, pharmacy, biomedical products and durable medical equipment.

About Alliqua, Inc.

Alliqua, Inc. (ALQA) ("Alliqua") is a biopharmaceutical company focused on the development, manufacturing, and distribution of proprietary transdermal wound care and drug delivery technologies. Alliqua's technology platform produces hydrogels, a 3-dimensional cross-linked network of water soluble polymers capable of numerous chemical configurations.

Alliqua currently markets its new line of 510(k) FDA-approved hydrogel products for wound care under the SilverSeal^® brand. Alliqua's electron beam production process, located at its 16,000 square foot GMP manufacturing facility in Langhorne, PA, allows Alliqua to develop and custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries. Additionally, Alliqua's drug delivery platform, in combination with certain active pharmaceutical ingredients, can provide pharmaceutical companies with a transdermal technology to enhance patient compliance and potentially extend the patent life of valuable drug franchises.

For additional information, please visit http://www.alliqua.com. To receive future press releases via email, please visit http://ir.stockpr.com/alliqua/email-alerts.

Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.

Legal Notice Regarding Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the our control that can make such statements untrue, including, but not limited to, inadequate capital, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and/or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that we will be able to develop new products on the basis of our technologies. In addition, other factors that could cause actual results to differ materially are discussed in our Annual Report on Form 10-K/A filed with the SEC on May 16, 2013, and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.

Contacts for Alliqua, Inc.
Steven Berger
Chief Financial Officer
+1(646)218-1450
info@alliqua.com

Investor Relations:
Dian Griesel Inc.
Cheryl Schneider
+1(212)825-3210
cschneider@dgicomm.com

Public Relations:
Dian Griesel Inc.
Susan Forman or Laura Radocaj
+1(212)825-3210
sforman@dgicomm.com
lradocaj@dgicomm.com

SOURCE Alliqua, Inc.